These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 24886378)
21. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. Jensen DM; Asselah T; Dieterich D; Foster GR; Sulkowski MS; Zeuzem S; Mantry P; Yoshida EM; Moreno C; Ouzan D; Wright M; Morano LE; Buynak R; Bourlière M; Hassanein T; Nishiguchi S; Kao JH; Omata M; Paik SW; Wong DK; Tam E; Kaita K; Feinman SV; Stern JO; Scherer J; Quinson AM; Voss F; Gallivan JP; Böcher WO; Ferenci P Ann Hepatol; 2016; 15(3):333-49. PubMed ID: 27049487 [TBL] [Abstract][Full Text] [Related]
22. Reviewing scientific manuscripts: A comprehensive guide for peer reviewers. Brown LM; David EA; Karamlou T; Nason KS J Thorac Cardiovasc Surg; 2017 Jun; 153(6):1609-1614. PubMed ID: 28526112 [No Abstract] [Full Text] [Related]
23. Workshop report treating hepatitis C in HIV-infected patients: where are we now? Perronne C Antivir Ther; 2005; 10(5):691-4. PubMed ID: 16152763 [TBL] [Abstract][Full Text] [Related]
24. HCV findings presented at EASL: long-term follow-up and the criteria of a cure. Lang L Gastroenterology; 2007 Jun; 132(7):2282-3. PubMed ID: 17570197 [No Abstract] [Full Text] [Related]
25. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline]. Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886 [TBL] [Abstract][Full Text] [Related]
26. Hepatitis C treatment, HAART and side effects. TreatmentUpdate; 2001; 13(7):7-8. PubMed ID: 11794865 [No Abstract] [Full Text] [Related]
27. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Forns X; Lawitz E; Zeuzem S; Gane E; Bronowicki JP; Andreone P; Horban A; Brown A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Scott J; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M Gastroenterology; 2014 Jun; 146(7):1669-79.e3. PubMed ID: 24602923 [TBL] [Abstract][Full Text] [Related]
28. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C. Aghemo A; Rumi MG; Colombo M Expert Rev Anti Infect Ther; 2009 Oct; 7(8):925-35. PubMed ID: 19803700 [TBL] [Abstract][Full Text] [Related]
29. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lawitz E; Lalezari JP; Hassanein T; Kowdley KV; Poordad FF; Sheikh AM; Afdhal NH; Bernstein DE; Dejesus E; Freilich B; Nelson DR; Dieterich DT; Jacobson IM; Jensen D; Abrams GA; Darling JM; Rodriguez-Torres M; Reddy KR; Sulkowski MS; Bzowej NH; Hyland RH; Mo H; Lin M; Mader M; Hindes R; Albanis E; Symonds WT; Berrey MM; Muir A Lancet Infect Dis; 2013 May; 13(5):401-8. PubMed ID: 23499158 [TBL] [Abstract][Full Text] [Related]
31. Factors impacting time to acceptance and publication for peer-reviewed publications. Toroser D; Carlson J; Robinson M; Gegner J; Girard V; Smette L; Nilsen J; O'Kelly J Curr Med Res Opin; 2017 Jul; 33(7):1183-1189. PubMed ID: 27977312 [TBL] [Abstract][Full Text] [Related]
32. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877 [TBL] [Abstract][Full Text] [Related]
33. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030 [TBL] [Abstract][Full Text] [Related]
34. Journal response types and times: the outcomes of manuscripts finalised for submission by the University of the Free State School of Medicine medical editor, South Africa. Joubert G; Mulder T; Steinberg WJ; Botes J Pan Afr Med J; 2020; 36():212. PubMed ID: 32963678 [TBL] [Abstract][Full Text] [Related]
35. [Treatment strategies of acute and chronic hepatitis C]. Gładysz A; Inglot M Przegl Epidemiol; 2002; 56 Suppl 5():10-5. PubMed ID: 15553066 [TBL] [Abstract][Full Text] [Related]
36. Perspective on Systematic Medical Literature Reviews and Meta-Analyses. Pepose JS; Foulks GN; Nelson JD; Erickson S; Lemp MA Am J Ophthalmol; 2020 Mar; 211():15-21. PubMed ID: 31811861 [TBL] [Abstract][Full Text] [Related]
37. [Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus]. Marcos Sánchez F; Albo Castaño MI; Casallo Blanco S Rev Clin Esp; 2007 Mar; 207(3):150-1; author reply 151-2. PubMed ID: 17397643 [No Abstract] [Full Text] [Related]
38. Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin. Calmus Y; Duvoux C; Pageaux G; Wolf P; Rostaing L; Vanlemmens C; Botta-Fridlund D; Dharancy S; Gugenheim J; Durand F; Néau-Cransac M; Boillot O; Chazouillères O; Samelson L; Boudjema K; Samuel D J Hepatol; 2012 Sep; 57(3):564-71. PubMed ID: 22613001 [TBL] [Abstract][Full Text] [Related]
39. [Long-acting interferon: studies on pegylated interferon]. Ma H; Wang H Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):78-9. PubMed ID: 11856520 [No Abstract] [Full Text] [Related]